You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
复旦张江(01349.HK)中期纯利升71.02%至8963万元
格隆汇 08-20 18:56

格隆汇8月20日丨复旦张江(01349.HK)公布,截至2019年6月30日止6个月,公司实现收入人民币3.91亿元(单位下同),同比增长32.12%;公司股东应占期内利润8963万元,同比增长71.02%;每股基本盈利0.0971元,不派息。

公告称,收益增长主要原因是本集团产品艾拉®(盐酸氨酮戊酸散,ALA)、里葆多®(盐酸多柔比星脂质体,Doxorubicin liposome)和复美达®(海姆泊芬,Hemoporfin)于回顾期内均销售良好,稳定增长。

2019年上半年,集团销售医疗产品收入约为3.89亿元(占总收入的99.7%),比2018年同期上升了36%。集团的主要产品艾拉®、里葆多®和复美达®,为集团的总收入分别贡献了52.6%、37.7%和8.6%。

研发方面,集团一贯采取较为保守和谨慎的研发项目资本化政策,仅针对技术上具有可行性,未来目的明确,风险基本可控并且很可能具备未来经济利益的研发项目进行资本化。因此,集团绝大部分的在研项目支出均於产生时确认为费用。期内,研究开发费用约为5119.6万元,比2018年同期增加16%,研究开发费用占收入比为13%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account